What is psilocybin-assisted therapy?

Psilocybin-assisted therapy is a structured therapeutic approach in which a carefully prepared dose of psilocybin is administered to a patient in a supervised clinical setting, with trained therapists or guides present throughout the experience. The psychedelic session is embedded within a broader therapeutic programme that includes preparatory sessions before dosing and integration sessions afterward. The therapy aims to use the altered state of consciousness produced by psilocybin to facilitate psychological breakthroughs, process difficult emotions, and support lasting changes in mood, behaviour, and wellbeing.

What conditions is psilocybin-assisted therapy being studied for?

Current clinical research is examining psilocybin-assisted therapy for a range of conditions, with the strongest evidence so far for major depressive disorder (including treatment-resistant depression), end-of-life anxiety and existential distress in people with terminal illness, alcohol use disorder, and tobacco (nicotine) addiction. Earlier-phase studies are also underway for OCD, PTSD, anorexia nervosa, and chronic pain. The FDA has granted Breakthrough Therapy designation for psilocybin in treatment-resistant depression and major depressive disorder, expediting the review process.

What happens during a psilocybin therapy session?

A typical psilocybin therapy session takes place in a comfortable room designed to feel calm and safe, often with a reclining couch, soft lighting, and curated music. After ingesting psilocybin, the patient lies down with eyeshades and headphones and is encouraged to turn attention inward. One or two trained therapists or guides are present throughout the 6–8 hour session, providing reassurance and support without directing the experience. Patients are encouraged to 'trust, let go, and be open.' Integration conversations begin the following day and continue over subsequent sessions to help the patient make sense of what arose.

Is psilocybin-assisted therapy safe?

Within carefully screened populations and properly supervised settings, psilocybin-assisted therapy has demonstrated a strong safety profile in clinical trials. Serious adverse events are rare. The most common risks are psychological: transient anxiety, confusion, or distress during the session, which can usually be managed with reassurance from the therapist. Psilocybin is not physically toxic at therapeutic doses and does not cause organ damage. Key contraindications include a personal or family history of schizophrenia or bipolar I disorder, use of serotonergic medications (including SSRIs and MAOIs), and active cardiovascular disease. Careful screening is essential to minimise risk.

Psilocybin-Assisted Therapy FAQ

Clear answers to the most common questions about clinical psilocybin therapy — how it works, who qualifies, what to expect, and what decades of research tell us about its risks and benefits.

⚠️ Educational purposes only. Not medical or legal advice. Always consult qualified professionals.

How Psilocybin-Assisted Therapy Works

Psilocybin-assisted therapy is a structured clinical protocol combining controlled administration of psilocybin with professional psychotherapeutic support. Unlike conventional pharmacotherapy, where a medication is taken daily and works through continuous receptor modulation, psilocybin therapy typically involves one to three high-dose sessions separated by weeks of preparatory and integrative psychotherapy. The approach is best documented through the landmark studies conducted at Johns Hopkins Center for Psychedelic and Consciousness Research and Imperial College London's Centre for Psychedelic Research.

In these protocols, participants undergo several preparatory meetings with trained therapists — often eight or more hours total — before the dosing session. During the session itself, which lasts approximately six to eight hours, the patient reclines on a couch in a carefully designed room furnished to resemble a comfortable living space rather than a clinical setting. Two therapists or guides sit with the patient throughout, offering reassurance and gentle direction without steering the experience. After the psilocybin session, integration therapy begins — a series of meetings focused on making meaning of what arose during the experience and translating those insights into lasting behavioural change.

Conditions Being Studied and Eligibility Considerations

Clinical trials have investigated psilocybin-assisted therapy across a range of conditions. The most robust evidence — including phase 2 and emerging phase 3 data — exists for treatment-resistant depression (TRD), end-of-life anxiety and existential distress in cancer patients, alcohol use disorder, and tobacco addiction. The 2022 phase 2b trial by COMPASS Pathways demonstrated significant reductions in depression scores at 25 mg, providing some of the strongest controlled evidence to date. Earlier open-label work by Roland Griffiths and colleagues showed that a single high-dose psilocybin session reduced cancer patients' anxiety and depression scores by more than 50% at a six-month follow-up.

Eligibility for clinical trial participation or, where legal, licensed treatment is determined by rigorous screening. Generally, candidates must be adults with a confirmed diagnosis in the target condition who have not responded adequately to conventional treatments. Exclusion criteria commonly include a personal or first-degree family history of psychosis or schizophrenia spectrum disorders, current use of lithium or tramadol (which carry seizure risk in combination with serotonergic agents), active suicidal ideation with intent, cardiovascular contraindications, and pregnancy. Age, current medications, and psychiatric comorbidities are all reviewed in depth during screening.

What to Expect During a Therapeutic Session

The dosing day begins with final preparation conversations, setting a clear intention and reviewing safety protocols. A typical therapeutic dose in clinical research ranges from 20 to 30 mg of synthetic psilocybin (equivalent roughly to 3–5 g of dried Psilocybe cubensis, though pharmaceutical purity is more consistent). Effects begin within 20 to 40 minutes and peak between 60 and 120 minutes, with the full session lasting five to seven hours. Eye shades and curated music playlists — such as those developed by researchers at Johns Hopkins — are standard tools to deepen inward focus.

Patients often report a dissolution of ordinary ego boundaries, vivid emotional memories, profound insights about personal relationships, and encounters with what they describe as a sense of unity or interconnectedness. Some experiences are challenging: anxiety, confusion, or difficult memories may surface. Therapists are trained to use the "LEAP" approach — Listen, Empathise, Accept, and Process — to guide clients through difficult moments without suppressing the experience prematurely. The principle, borrowed partly from Stanislav Grof's holotropic model, is that difficult material that arises and is met with openness can produce therapeutic breakthroughs.

Costs, Access, and the Current Legal Landscape

Access to psilocybin-assisted therapy outside of clinical trials remains extremely limited. As of 2026, Oregon is the only US state with a functioning licensed service centre model under Measure 109, where facilitated psilocybin sessions (not technically therapy, as no diagnosis or treatment relationship is required) cost between $1,500 and $3,500 per session, none of which is covered by insurance. Colorado's Proposition 122 is in the early stages of regulation. In Australia, psilocybin was rescheduled to Schedule 8 in February 2023, allowing authorised psychiatrists to prescribe it for TRD from July 2023 — a world first in terms of mainstream prescribing, though logistical and cost barriers remain high.

For those unable to access licensed services, clinical trials remain the primary legal route. ClinicalTrials.gov lists dozens of ongoing studies, many of which provide the compound, therapy, and monitoring at no cost to participants. Organisations such as MAPS (Multidisciplinary Association for Psychedelic Studies), the Usona Institute, and the Beckley Foundation maintain updated information on enrolment opportunities and publish their research protocols openly.

Frequently Asked Questions

Is psilocybin-assisted therapy the same as taking magic mushrooms recreationally?

No. Clinical psilocybin therapy involves pharmaceutical-grade psilocybin of verified purity and dose, administered in a carefully controlled setting with trained therapists present before, during, and after the session. Recreational use lacks dose certainty, therapeutic preparation, clinical oversight, and structured integration support. The set (mindset and intention), setting (environment), and support are considered central to therapeutic outcomes — elements absent in most recreational contexts.

How many therapy sessions does the treatment involve?

Most clinical protocols involve one to three psilocybin dosing sessions, surrounded by substantially more hours of non-drug psychotherapy. For example, the Johns Hopkins depression trial used two psilocybin sessions separated by one week, bookended by approximately five hours of preparatory therapy and three or more hours of integration therapy. The total therapeutic contact time is typically 15 to 25+ hours. Single-session protocols are also being studied, particularly for end-of-life distress.

Can psilocybin therapy make my mental health worse?

Adverse reactions are possible and are taken seriously in clinical protocols. Transient increases in anxiety, difficult emotional material surfacing, and challenging experiences during the session occur in a minority of participants. However, in rigorously screened populations with proper support, serious lasting harm is rare. Psilocybin is not recommended for people with personal or family histories of psychosis, bipolar I disorder, or certain other conditions due to elevated risk of adverse psychiatric outcomes. This is why comprehensive screening is essential.

What does the research say about long-term outcomes?

Follow-up data from multiple trials are encouraging. A 2016 Johns Hopkins study found that 80% of smokers who received psilocybin-assisted therapy had abstained at a 6-month follow-up — a rate far exceeding most existing cessation treatments. Depression trials report significant symptom reductions sustained at 3-, 6-, and in some cases 12-month follow-ups. A 2021 publication in the New England Journal of Medicine showed psilocybin therapy to be comparable to escitalopram (a standard SSRI) for major depressive disorder on some outcome measures, while producing faster initial response.

Who conducts psilocybin therapy sessions — doctors, therapists, or someone else?

In clinical trials, facilitators are typically licensed mental health professionals (psychologists, psychiatrists, social workers, or counsellors) who have completed specialised training in psychedelic-assisted therapy. Organisations such as MAPS, the California Institute of Integral Studies (CIIS), and Fluence offer training programmes. In Oregon's legal service-centre model, "facilitators" are separately licensed by the Oregon Psilocybin Services programme and need not be licensed therapists, though many have clinical backgrounds.

Do I need to stop my current medications before therapy?

This is a medical decision made case-by-case by the supervising clinician. SSRIs and SNRIs can blunt the psychedelic response by downregulating 5-HT2A receptors, so many protocols require a supervised taper before dosing. Lithium and tramadol carry seizure risk and must be discontinued. MAOIs can dangerously potentiate the psilocybin effect and require a wash-out period. Never alter your medication regimen without guidance from the prescribing physician and the therapy team.

Is psilocybin therapy physically safe?

Psilocybin has a remarkably low physiological toxicity profile. It produces no organ toxicity at typical doses, is not physically addictive, and does not cause respiratory depression. The primary physiological risks are transient increases in heart rate and blood pressure during peak effects. For people with significant cardiovascular conditions, this warrants careful medical screening. The 2008 Johns Hopkins safety guidelines, updated in 2016 and published in Psychopharmacology, outline the rigorous precautions used to minimise risk in research settings.

What is the role of music in psilocybin therapy sessions?

Music is considered a core component of the therapeutic container. Research teams, notably at Johns Hopkins and NYU Langone, have developed specific playlists designed to support emotional opening, facilitate difficult passages, and bring the experience to a gentle close. The music typically follows an arc: ambient and grounding at the start, emotionally evocative and orchestral at the peak, and softly returning the person to ordinary awareness toward the end. Studies by researchers including Frederick Barrett have found that music-evoked emotion during sessions correlates with therapeutic outcomes.

How do I find a legitimate clinical trial to participate in?

The primary resource is ClinicalTrials.gov, the US National Library of Medicine's registry of clinical research. Searching "psilocybin" returns dozens of active studies across conditions including depression, PTSD, OCD, anorexia nervosa, and addiction. The MAPS website (maps.org) and Usona Institute (usonainstitute.org) list their own ongoing trials. In the UK, the Imperial College London and King's College London both run psilocybin research programmes with open recruitment windows. Always verify that any trial you consider is registered, IRB/ethics-board approved, and conducted by credentialled researchers.

What happens after the psilocybin session ends?

The immediate post-session period involves a return to ordinary consciousness over one to two hours, often accompanied by a debrief conversation with the therapist. Most protocols require someone to accompany the patient home and recommend a quiet, restful evening. Integration sessions — typically two to five formal meetings over the following weeks — are considered as important as the dosing session itself. Without integration, insights gained during the experience may fade or be difficult to apply to daily life. Many participants also maintain personal practices such as journaling, meditation, or sharing reflections with a trusted community as part of ongoing integration.